MBD2 and prostate cancer: We tested the effect of JMJD3/UTX demethylase inhibitor GSK-J4 on five prostate cancer cell lines: R1-AD1 (AR-WT), R1-D567 and R1-I567 (ARΔLBD), CWR22Rv-1 (CRPC cell line that expresses both AR WT and AR with deletion), and PC3 (low levels of AR expression) by the direct cell count after 72h of treatment.